Progress has been made in the treatment of advanced non-small-cell lung cancer (NSCLC) using small-molecule tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, targeting epidermal growth factor receptor (EGFR) (Lynch et al, 2006). Here, EGFR is linked to non-small cell lung carcinoma.